More Fields

Filters

Profiles which have:

Recent Changes

Profiles with recent changes to:
Sign up to Download

1-11 of 11 results

  • www.tibsovopro.com
  • 2
If differentiation syndrome is suspected, initiate dexamethasone 10 mg IV every 12 hours (or an equivalent dose of an alternative oral or IV corticosteroid) and hemodynamic monitoring until improvement. If concomitant noninfectious leukocytosis is..
Relevance: 110.733795
  • trazimera.pfizerpro.com
  • 2
About TRAZIMERA Loading TRAZIMERA is FDA approved across all indications of Herceptin® 1 Indications Loading FDA-approved biosimilars such as trastuzumab-qyyp (TRAZIMERA®) are recommended as appropriate substitutes for trastuzumab in the NCCN..
Relevance: 110.733795
  • www.erleadahcp.com
  • 1
The information you provide will be used by Janssen Biotech, Inc., or affiliates, and our service providers to have a Janssen representative contact you. Our Privacy Policy further governs the use of the information you provide. By providing the..
Relevance: 109.33458
  • www.alunbrig.com
  • 1
Muscle pain, tenderness, and weakness (myalgia). ALUNBRIG may increase the level of an enzyme in your blood called creatine phosphokinase (CPK), which may be a sign of muscle damage. Your healthcare provider will do blood tests to check your blood..
Relevance: 109.30407
  • www.thinkdeepmm.com
Over the past few years, there have been significant developments in the treatment of multiple myeloma. However, the therapies are not cures, so all patients will eventually relapse. In a recent real-world study, researchers looked to understand the..
Relevance: 109.30407
  • www.onuregpro.com
† NCCN Guidelines® Category 1, Preferred recommendation applies to AML patients age ≥60 in the post-induction setting who received previous intensive therapy and were unable to receive any of all recommended consolidation, regardless of risk status...
Relevance: 107.36934
  • www.pylarify.com
  • 5
  • 8
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way... Learn about PYLARIFY®, a new FDA-approved imaging agent assessing patients with..
Relevance: 107.033615
  • www.polivy-hcp.com
  • 1
POLIVY in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade..
Relevance: 107.033615
  • www.inrebicpro.com
NCCN Guidelines® recommend fedratinib (INREBIC®) as an initial treatment option (Category 1) for patients with higher-risk (intermediate-2 or high-risk) MF who have platelet counts ≥50 × 10 9/L... *NCCN makes no warranties of any kind whatsoever..
Relevance: 106.99269
  • hcp.jakafi.com
  • 1
  • 2
§ Category 1: Based upon high-level evidence, there is uniform National Comprehensive Cancer Network® (NCCN®) consensus that the intervention is appropriate. 4... References: 1. Jakafi [package insert]. Wilmington, DE: Incyte Corporation. 2...
Relevance: 106.99269
  • www.nccn.org
  • 11
  • 14
  • 37
NCCN is a not-for-profit alliance of 33 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better..
Relevance: 28.36866